Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2002

View Archived Issues

Adenosine A2A receptor antagonists can relieve parkinsonian disability

Icos reviews second-quarter progress

Tetrahydrocannabinol is safe and effective in the treatment of agitation associated with AD

New data on donepezil presented at Alzheimer's Disease conference

Further characterization of the effects of galantamine

Vinpocetine compared to donepezil and galantamine against scopolamine-induced cognitive deficits

APC-0576 inhibits proinflammatory cytokine-induced chemokine production in human endothelial cells

Vertex presents novel JNK inhibitors for neurodegenerative diseases, etc.

Synthetic MMP inhibitor Ro-28-2653 undergoes in vitro and in vivo testing

Novel steroid 17,20 lyase inhibitors in early development at Takeda

Nippon Chemiphar researchers identify PPAR agonists with potential in obesity and other disorders

Aventis claims novel antiarrhythmic Kv1.5 channel blockers

Novel antibiotic identified in Coniochaeta ellipsoidea cultures

Researchers at Aventis report the isolation and activity of klainetins

Novel Na+/HCO3- cotransporter inhibitors described in recent patent

Clofarex enters trials in AML, ALL and solid tumors

ADVENT trial results support expanded indications for Niaspan

E.U. approval for Zavesca recommended; OGS and Actelion sign marketing agreement

Valdecoxib receives positive opinion in E.U.

Tularik sums up second-quarter achievements

SignalGene updates progress of SG-292

Final part of Aldurazyme BLA submitted, priority review requested

E.U. approval for cancer imaging agent Flucis

N20C: a selective NMDA receptor open channel blocker with a neuroprotective profile

Swedish approval for dutasteride for benign prostatic hyperplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...